Login / Register Submit Your Article
cover
Article Menu

Journal Browser
Vol. 2 (2024)
Vol. 1 (2023)
Indexing and Partners

Google scholar

Crossref

Open Access Review

Studying the association between some genetic polymorphisms and Doxorubicin-Induced Cardiotoxicity

by Enas A. El-Shorbagy 1,* ,  Amira B. Kassem 2 ,  Noha A. El‑Bassiouny 2 ,  Ahmad Salahuddin 3  and  Nermeen Nabeel Abuelsoud 1
1
Clinical Pharmacy and Practice Pharmacy Department, Faculty of Pharmacy, Egyptian Russian University, Cairo 11829, Egypt.
2
Clinical pharmacy and pharmacy practice Department, Faculty of pharmacy, Damanhour University, Egypt.
3
Biochemistry Department, Faculty of Pharmacy, Damanhur University, Damanhur 22514, Egypt.
*
Author to whom correspondence should be addressed.
IJCMR  2024, 26; 2(3), 26; https://doi.org/10.61466/ijcmr2030001
Received: 3 March 2024 / Accepted: 28 April 2024 / Published Online: 2 May 2024
View Full-Text
Download PDF

Abstract

Anthracyclines are a crucial component of chemotherapy regimens used to treat a range of malignancies in children and adults. However, cardiac dysfunction and heart failure frequently limit the therapeutic efficacy of anthracyclines. The risk of heart dysfunction increases with increasing doses of anthracycline. Cardiotoxicity is a challenging side effect of DOX, which is cumulative and irreversible; this necessitates assessing the cardiac functions in cancer patients before and after the use of    DOX to avoid permanent cardiac damage. Serial measurements of left ventricle ejection fraction (LVEF) are commonly used for cardiac monitoring during anthracycline treatment. In some studies, cardiotoxicity was defined as LVEF decrease by an absolute 10% and/or below 55%; in others, cardiotoxicity was defined as a decrease below 45%. A serious disadvantage of this test is radioactivity exposure and the low predictability of pre-symptomatic cardiac damage. Blood cardiac biomarkers, such as cardiac troponins and B-type natriuretic peptide (BNP), have been used in heart failure diagnostics. Susceptibility to DOX cardiotoxicity is largely individual, with some patients developing cardiomyopathy at low doses and others tolerating much higher cumulative doses, and this may suggest the presence of genetic predisposition factors. Genetic variations in CBR3 and ABCC1 genes were suggested to contribute to DOX adverse effects. This review highlights the genetic basis for anthracycline-related cardiac dysfunction, focuses on particular genes that have been implicated in innate predisposition to ACT, and assessment of cardiotoxicity.

Keywords: Breast cancer, Polymorphisms, Doxorubicin, Cardiotoxicity.;
Copyright: © 2024 by El-Shorbagy, Kassem, El‑Bassiouny, Salahuddin and Abuelsoud. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY) (Creative Commons Attribution 4.0 International License). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

Share and Cite

ACS Style
El-Shorbagy, E. A.; Kassem, A. B.; El‑Bassiouny, N. A.; Salahuddin, A.; Abuelsoud, N. N. Studying the association between some genetic polymorphisms and Doxorubicin-Induced Cardiotoxicity. International Journal of Clinical Medical Research, 2024, 2, 26. https://doi.org/10.61466/ijcmr2030001
AMA Style
El-Shorbagy E A, Kassem A B, El‑Bassiouny N A, Salahuddin A, Abuelsoud N N. Studying the association between some genetic polymorphisms and Doxorubicin-Induced Cardiotoxicity. International Journal of Clinical Medical Research; 2024, 2(3):26. https://doi.org/10.61466/ijcmr2030001
Chicago/Turabian Style
El-Shorbagy, Enas A.; Kassem, Amira B.; El‑Bassiouny, Noha A.; Salahuddin, Ahmad; Abuelsoud, Nermeen N. 2024. "Studying the association between some genetic polymorphisms and Doxorubicin-Induced Cardiotoxicity" International Journal of Clinical Medical Research 2, no.3:26. https://doi.org/10.61466/ijcmr2030001

Article Metrics

Article Access Statistics

References

  1. Sagi JC, Kutszegi N, Kelemen A, et al. Pharmacogenetics of anthracyclines. Pharmacogenomics. 2016; 17: 1075- 1087
  2. Hortobagyi GN. Anthracyclines in the treatment of cancer. An overview. Drugs. 1997; 54(suppl 4): 1- 7.
  3. World Health Organization Model List of Essential Medicines, 21st List, 2019. Geneva: World Health Organization; 2019. Licence: CC BYNC-SA 3.0 IGO.
  4. Henriksen PA. Anthracycline cardiotoxicity: an update on mechanisms, monitoring and prevention. Heart. 2018; 104: 971- 977.
  5. Lipshultz SE, Lipsitz SR, Sallan SE, et al.Chronic progressive cardiac dysfunction years after doxorubicin therapy for childhood acute lymphoblastic leukemia. J Clin Oncol 2005;23:2629–36.
  6. van der Pal HJ, van Dalen EC, Hauptmann M, et al. Cardiac function in 5-year survivors of childhood cancer: a long-term follow-up study.Arch Intern Med 2010;170:1247–55.
  7. Yahalom J, Portlock CS. Long-term cardiac and pulmonary complications of cancer therapy. Hematol Oncol Clin North Am 2008;22:305–18.vii.
  8. Adams MJ, Lipshultz SE. Pathophysiology of anthracycline- and radiation-associated cardiomyopathies: implications for screening and prevention. Pediatr Blood Cancer 2005;44:600–6.
  9. Armstrong GT, Oeffinger KC, Chen Y, et al. Modifiable risk factors and major cardiac events among adult survivors of childhood cancer. J ClinOncol 2013;31:3673–80.
  10. Lotrionte M, Biondi-Zoccai G, Abbate A, et al. Review and meta-analysis of incidence and clinical predictors of anthracycline cardiotoxicity. Am J Cardiol 2013;112:1980–4.
  11. Kremer LC, van der Pal HJ, Offringa M, van Dalen EC, Voute PA. Frequency and risk factors of subclinical cardiotoxicity after anthracycline therapy in children: a systematic review. Ann Oncol 2002;13:819–29.
  12. Bhatia S. Role of genetic susceptibility in development of treatment-related adverse outcomes in cancer survivors. Cancer Epidemiol Biomarkers Prev 2011;20:2048–67.
  13. Jensen BC, McLeod HL. Pharmacogenomics as a risk mitigation strategy for chemotherapeutic cardiotoxicity. Pharmacogenomics 2013;14: 205–13.
  14. Wang X, Liu W, Sun CL, et al. Hyaluronan synthase 3 variant and anthracycline-related cardiomyopathy: a report from the children’s oncology group. J Clin Oncol 2014;32:647–53.
  15. Wang X, Sun CL, Quinones-Lombrana A, et al. CELF4 variant and anthracycline-related cardiomyopathy: a Children’s Oncology Group Genome-Wide Association Study. J Clin Oncol 2016;34:863–70.
  16. Aminkeng F, Bhavsar AP, Visscher H, et al.Canadian Pharmacogenomics Network for Drug Safety Consortium. A coding variant in RARG confers susceptibility to anthracycline-induced cardiotoxicity in childhood cancer. Nat Genet 2015;47:1079–84.
  17. Visscher H, Rassekh SR, Sandor GS, et al., CPNDS Consortium. Genetic variants in SLC22A17 and SLC22A7 are associated with anthracycline induced cardiotoxicity in children. Pharmacogenomics 2015;16:1065–76.
  18. Visscher H, Ross CJ, Rassekh SR, et al. Canadian Pharmacogenomics Network for Drug Safety Consortium. Pharmacogenomic prediction of anthracycline-induced cardiotoxicity in children. J Clin Oncol 2012;30:1422–8.
  19. Visscher H, Ross CJ, Rassekh SR, et al., CPNDS Consortium. Validation of variants in SLC28A3 and UGT1A6 as genetic markers predictive of anthracycline-induced cardiotoxicity in children. Pediatr Blood Cancer 2013;60:1375–81.
  20. Wojnowski L, Kulle B, Schirmer M, et al. NAD(P)H oxidase and multidrug resistance protein genetic polymorphisms are associated with doxorubicin-induced cardiotoxicity. Circulation 2005;112:3754–62.
  21. Blanco JG, Leisenring WM, Gonzalez-Covarrubias VM, et al. Genetic polymorphisms in the carbonyl reductase 3 gene CBR3 and the NAD(P)H:quinone oxidoreductase 1 gene NQO1 in patients who developed anthracycline-related congestive heart failure after childhood cancer. Cancer 2008;112:2789–95.
  22. Blanco JG, Sun CL, Landier W, et al. Anthracycline-related cardiomyopathy after childhood cancer: role of polymorphisms in carbonyl reductase genes—a report from the Children’s Oncology Group. J Clin Oncol 2012;30:1415–21.
  23. Armenian S, Bhatia S. Predicting and preventing anthracycline-related cardiotoxicity. Am Soc Clin Oncol Educ Book 2018:3–12.
  24. Cascales A., Pastor-Quirante F., Sanchez-Vega B. Association of anthracycline-related cardiac histological lesions with NADPH oxidase functional polymorphisms. Oncologist. 2013;18:446–453
  25. Serrano J., Palmeira C.M., Kuehl D.W., Wallace K.B. Cardioselective and cumulative oxidation of mitochondrial DNA following subchronic doxorubicin administration. Biochim Biophys Acta. 1999;1411:201–205.
  26. Arola O.J., Saraste A., Pulkki K., Kallajoki M., Parvinen M., Voipio-Pulkki L.M. Acute doxorubicin cardiotoxicity involves cardiomyocyte apoptosis. Cancer Res. 2000;60:1789–1792.
  27. Rebbaa A., Chou P.M., Emran M., Mirkin B.L. Doxorubicin-induced apoptosis in caspase-8-deficient neuroblastoma cells is mediated through direct action on mitochondria. Cancer Chemother Pharmacol. 2001;48:423–428.
  28. Zhang S., Liu X., Bawa-Khalfe T. Identification of the molecular basis of doxorubicin-induced cardiotoxicity. Nat Med. 2012;18:1639–1642.
  29. Herman E.H., Zhang J., Hasinoff B.B., Clark J.R., Jr., Ferrans V.J. Comparison of the structural changes induced by doxorubicin and mitoxantrone in the heart, kidney and intestine and characterization of the Fe(III)-mitoxantrone complex. J Mol Cell Cardiol. 1997;29:2415–2430.
  30. Kim H.D., Kim C.H., Rah B.J., Chung H.I., Shim T.S. Quantitative study on the relation between structural and functional properties of the hearts from three different mammals. Anat Rec. 1994;238:199–206.
  31. De Angelis A., Piegari E., Cappetta D. Anthracycline cardiomyopathy is mediated by depletion of the cardiac stem cell pool and is rescued by restoration of progenitor cell function. Circulation. 2010;121:276–292.
  32. Lebrecht D., Kokkori A., Ketelsen U.P., Setzer B., Walker U.A. Tissue-specific mtDNA lesions and radical-associated mitochondrial dysfunction in human hearts exposed to doxorubicin. J Pathol. 2005;207:436–444.
  33. Lebrecht D., Walker U.A. Role of mtDNA lesions in anthracycline cardiotoxicity. Cardiovasc Toxicol. 2007;7:108–113.
  34. Yeh E.T.H., Ewer M.S., Moslehi J. Mechanisms and clinical course of cardiovascular toxicity of cancer treatment I. Oncology. Semin Oncol. 2019;46:397–402.
  35. Bonow RO, Mann DL, Zipes DP, Libby P. Braunwald's Heart Disease: A Textbook of Cardiovascular Medicine. 9th ed. Philadelphia, Pa. Saunders Elsevier; 2012.
  36. Cardinale D, Colombo A, Lamantia G, Colombo N, Civelli M, De Giacomi G, et al. Anthracyclineinduced cardiomyopathy: clinical relevance and response to pharmacologic therapy. J Am Coll Cardiol 2010; 55:213–220.
  37. Ganz WI, Sridhar KS, Ganz SS Gonzalez R, Chakko S, Serafini A. Review of tests for monitoring doxorubicin-induced cardiomyopathy. Oncology 1996; 53:461–470.
  38. Iqbal N, Wentworth B, Choudhary R, Landa Ade L, Kipper B, Fard A, et al. Cardiac biomarkers: New tools for heart failure management. Cardiovasc Diagn Ther 2012; 2:147–164
  39. Berkman AM, Hildebrandt MAT, Landstrom AP. The genetic underpinnings of anthracycline-induced cardiomyopathy predisposition. Clinical Genetics. 2021 Aug;100(2):132-143.
  40. Blanco JG, Sun CL, Landier W, et al. Anthracycline-related cardiomyopathy after childhood cancer: role of polymorphisms in carbonyl reductase genes—a report from the Children’s Oncology Group. J Clin Oncol 2012;30:1415–21
  41. Cascorbi I. Role of pharmacogenetics of ATP-binding cassette transporters in the pharmacokinetics of drugs. Pharmacol Ther. 2006; 112: 457- 473
  42. Schaupp C.M., White C.C., Merrill G.F., Kavanagh T.J. Metabolism of doxorubicin to the cardiotoxic metabolite doxorubicinol is increased in a mouse model of chronic glutathione deficiency: a potential role for carbonyl reductase 3. Chem Biol Interact. 2015;234:154–161.
  43. Cascorbi I. Role of pharmacogenetics of ATP-binding cassette transporters in the pharmacokinetics of drugs. Pharmacol Ther. 2006; 112: 457- 473.
  44. Couture L, Nash J, Turgeon J. Role of ATP-binding cassette transporters in drug distribution to the heart and protection from toxic compounds. Heart Metab. 2007; 35: 16- 21
  45. Cole SP. Multidrug resistance protein 1 (MRP1, ABCC1), a "multitasking" ATP-binding cassette (ABC) transporter. J Biol Chem. 2014; 289: 30880- 30888.
  46. Parekh H, Wiesen K, Simpkins H. Acquisition of taxol resistance via P-glycoprotein- and non-P-glycoprotein-mediated mechanisms in human ovarian carcinoma cells. Biochem Pharmacol. 1997; 53: 461- 470.
  47. Huang JF, Wen CJ, Zhao GZ, et al. Overexpression of ABCB4 contributes to acquired doxorubicin resistance in breast cancer cells in vitro. Cancer Chemother Pharmacol. 2018; 82: 199- 210.
  48. Huang JF, Wen CJ, Zhao GZ, et al. Overexpression of ABCB4 contributes to acquired doxorubicin resistance in breast cancer cells in vitro. Cancer Chemother Pharmacol. 2018; 82: 199- 210.
  49. Thorn CF, Oshiro C, Marsh S, et al. Doxorubicin pathways: pharmacodynamics and adverse effects. Pharmacogenet Genom. 2011; 21: 440- 446.
  50. Pratt S, Shepard RL, Kandasamy RA, Johnston PA, Perry W 3rd, Dantzig AH. The multidrug resistance protein 5 (ABCC5) confers resistance to 5-fluorouracil and transports its monophosphorylated metabolites. Mol Cancer Ther. 2005; 4: 855- 863.
  51. Semsei AF, Erdelyi DJ, Ungvari I, et al. ABCC1 polymorphisms in anthracycline-induced cardiotoxicity in childhood acute lymphoblastic leukaemia. Cell Biol Int. 2012; 36: 79- 86.
  52. Vulsteke C, Pfeil AM, Maggen C, et al. Clinical and genetic risk factors for epirubicin-induced cardiac toxicity in early breast cancer patients. Breast Cancer Res Treat. 2015; 152: 67- 76.
  53. Wojnowski L, Kulle B, Schirmer M, et al. NAD(P)H oxidase and multidrug resistance protein genetic polymorphisms are associated with doxorubicin-induced cardiotoxicity. Circulation. 2005; 112: 3754- 3762.
  54. Visscher H, Rassekh SR, Sandor GS, et al. Genetic variants in SLC22A17 and SLC22A7 are associated with anthracycline-induced cardiotoxicity in children. Pharmacogenomics. 2015; 16: 1065- 1076.
  55. Sagi JC, Egyed B, Kelemen A, et al. Possible roles of genetic variations in chemotherapy related cardiotoxicity in pediatric acute lymphoblastic leukemia and osteosarcoma. BMC Cancer. 2018; 18: 704.
  56. Krajinovic M, Elbared J, Drouin S, et al. Polymorphisms of ABCC5 and NOS3 genes influence doxorubicin cardiotoxicity in survivors of childhood acute lymphoblastic leukemia.
  57. Armenian SH, Ding Y, Mills G, et al. Genetic susceptibility to anthracycline-related congestive heart failure in survivors of haematopoietic cell transplantation. Br J Haematol. 2013; 163: 205- 213.
  58. Hertz DL, Caram MV, Kidwell KM, et al. Evidence for association of SNPs in ABCB1 and CBR3, but not RAC2, NCF4, SLC28A3 or TOP2B, with chronic cardiotoxicity in a cohort of breast cancer patients treated with anthracyclines. Pharmacogenomics. 2016; 17: 231- 240.
  59. McOwan TN, Craig LA, Tripdayonis A, et al. Evaluating anthracycline cardiotoxicity associated single nucleotide polymorphisms in a paediatric cohort with early onset cardiomyopathy.
  60. van Dalen EC, Michiels EM, Caron HN, Kremer LC. Different anthracycline derivates for reducing cardiotoxicity in cancer patients. Cochrane Database Syst Rev. 2010; 5:CD005006.
  61. Armenian SH, Armstrong GT, Aune G, et al. Cardiovascular disease in survivors of childhood cancer: insights into epidemiology, pathophysiology, and prevention. J Clin Oncol. 2018; 36: 2135- 2144.
  62. Lyon AR, Dent S, Stanway S, et al. Baseline cardiovascular risk assessment in cancer patients scheduled to receive cardiotoxic cancer therapies: a position statement and new risk assessment tools from the Cardio-Oncology Study Group of the Heart Failure Association of the European Society of Cardiology in collaboration with the International Cardio-Oncology Society. Eur J Heart Fail. 2020; 22: 1945- 1960.
  63. Chaix MA, Parmar N, Kinnear C, et al. Machine Learning Identifies Clinical and Genetic Factors Associated With Anthracycline Cardiotoxicity in Pediatric Cancer Survivors. JACC Cardiooncol. 2020; 2: 690- 706.
  64. Skitch A, Mital S, Mertens L, et al. Novel approaches to the prediction, diagnosis and treatment of cardiac late effects in survivors of childhood cancer: a multi-centre observational study. BMC Cancer. 2017; 17: 519
  65. Vulsteke C, Pfeil AM, Maggen C, et al. Clinical and genetic risk factors for epirubicin-induced cardiac toxicity in early breast cancer patients. Breast Cancer Res Treat. 2015; 152: 67- 76.
  66. Armenian S.H., Yang D., Teh J.B. Prediction of cardiovascular disease among hematopoietic cell transplantation survivors. Blood Adv. 2018;2:1756–1764.